RE:RE:RE:RE:SBMAll the delays are nerve-wracking. The small financial rounds annoying. I do not much care about the value of the upfront & milestone payment. If the management can close a deal with good conditions Sirona will be a very lucrative (special long-term) investment.
The global roll-out will be a big happening. IF the deal is coming, IF what I still believe, the roll-out can come sooner than many people think. A lot of preliminary work is probably done already...
for example, Allergan can increase -> with only 1% of Skin Lightening the market shares (USD 23 Bn by 2020) = 230 MUSD -> the sales from about 170 MUSD to 400 MEUR.
Do not understand me wrong, Allergan would be a very good partner but I still hope it is L’Oral or a big Chinese partner. Shiseido would be the jackpot.
Read more at https://www.stockhouse.com/companies/bullboard?symbol=v.sbm&postid=26543061#6KzvsYL2YCTkDGiA.99
Allergan Q2 Earnings A better than expected 2nd quarter earnings but the Skin Care division performed poorly especially internationally. Allergan has to act here - either divest or invest.
And luckily there are also other companies than Allergan :)
SECOND QUARTER 2017 EARNINGS CONFERENCE CALL
[url=file:///C:/Users/Michael/Downloads/Q2%202017%20Earnings%20Deck%208-3-17%20FINAL.pdf][/url]
2017
2016
US Specialized Therapeutics Product Revenue (3 month)
Skin Care 38.7 46.8 (8.1) (17.3)%
SkinMedica® 25.4 29.1 (3.7) (12.7)%
Latisse® 13.3 17.7 (4.4) (24.9)%
US Specialized Therapeutics Product Revenue (6 month)
Skin Care 80.3 93.2 (12.9) (13.8)%
SkinMedica® 53.4 55.7 (2.3) (4.1)%
Latisse® 26.9 37.5 (10.6) (28.3)%
International Product Revenue (3 month)
Skin Care 2.7 3.2 (0.5) (15.6)%
International Product Revenue (6 month)
Skin Care 4.9 5.8 (0.9) (15.5)%